K.J. Harrison & Partners Inc acquired a new stake in Natera, Inc. (NASDAQ:NTRA – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 18,850 shares of the medical research company’s stock, valued at approximately $5,117,000.
A number of other large investors have also recently added to or reduced their stakes in the stock. Trust Co. of Vermont bought a new stake in shares of Natera during the 2nd quarter worth $26,000. Reflection Asset Management acquired a new stake in shares of Natera during the 4th quarter worth approximately $29,000. Elevation Wealth Partners LLC bought a new stake in Natera in the 2nd quarter valued at $30,000. Palladiem LLC bought a new stake in Natera in the fourth quarter valued at about $31,000. Finally, Horizon Investments LLC bought a new stake in shares of Natera in the 3rd quarter valued at approximately $32,000. Institutional investors own 99.90% of the company’s stock.
Wall Street Analyst Weigh In
NTRA has been the subject of a number of recent analyst reports. Sanford C. Bernstein started coverage on shares of Natera in a research report on Friday, June 26th. They set an “outperform” rating and a $310.00 target price for the company. Barclays reissued an “overweight” rating and issued a $340.00 target price on shares of Natera in a research note on Friday, August 7th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $315.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Wolfe Research assumed coverage on Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $319.38.
Natera Stock Up 1.4%
NASDAQ:NTRA opened at $314.18 on Tuesday. Natera, Inc. has a twelve month low of $156.71 and a twelve month high of $326.03. The firm has a market capitalization of $45.29 billion, a price-to-earnings ratio of -231.01 and a beta of 1.51. The stock’s 50 day moving average price is $265.78 and its two-hundred day moving average price is $226.82.
Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million for the quarter, compared to analyst estimates of $661.24 million. During the same period in the prior year, the firm posted ($0.74) earnings per share. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. As a group, analysts anticipate that Natera, Inc. will post -1.11 earnings per share for the current year.
Insider Activity at Natera
In related news, insider Solomon Moshkevich sold 3,410 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the transaction, the insider directly owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares of the company’s stock, valued at $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 181,045 shares of company stock worth $41,330,968 in the last three months. 5.05% of the stock is owned by company insiders.
Natera Company Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
